Fintel reports that on January 28, 2026, Barclays initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Overweight recommendation.
Analyst Price Forecast Suggests 10.28% Upside
As of January 14, 2026, the average one-year price target for Tyra Biosciences is $34.24/share. The forecasts range from a low of $30.30 to a high of $38.85. The average price target represents an increase of 10.28% from its latest reported closing price of $31.05 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Tyra Biosciences is 21MM. The projected annual non-GAAP EPS is -1.06.
What is the Fund Sentiment?
There are 231 funds or institutions reporting positions in Tyra Biosciences. This is an decrease of 43 owner(s) or 15.69% in the last quarter. Average portfolio weight of all funds dedicated to TYRA is 0.79%, an increase of 20.75%. Total shares owned by institutions decreased in the last three months by 2.49% to 57,075K shares. 
The put/call ratio of TYRA is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 12,199K shares representing 22.86% ownership of the company. No change in the last quarter.
Nextech Invest holds 4,056K shares representing 7.60% ownership of the company. No change in the last quarter.
Alta Partners Management Company holds 3,823K shares representing 7.16% ownership of the company. In its prior filing, the firm reported owning 4,080K shares , representing a decrease of 6.72%. The firm increased its portfolio allocation in TYRA by 1.98% over the last quarter.
Bvf holds 3,650K shares representing 6.84% ownership of the company. In its prior filing, the firm reported owning 3,944K shares , representing a decrease of 8.07%. The firm increased its portfolio allocation in TYRA by 53.49% over the last quarter.
Canaan Partners XI holds 3,608K shares representing 6.76% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
